Recruiting

Incidence of Postoperative Diaphragmatic Dysfunction in Pregnant Women With Preeclampsia

Preeclampsia with severe features remains a leading contributor to maternal morbidity and mortality, particularly in low- and middle-income countries. It is defined by hypertension and involvement of multiple organ systems, including renal, hepatic, hematologic, and neurologic pathways. The interplay of endothelial dysfunction, capillary leakage, and disrupted fluid balance in these patients increases their susceptibility to perioperative pulmonary complications. Although respiratory complications in preeclampsia…

ClinicalTrials.gov IDNCT07443345
PhaseNot Applicable
Enrollment52
SponsorCairo University
Age20 Years
SexFEMALE
I'm interested View official listing

Conditions studied

Preecalmpsia

About this study

Preeclampsia with severe features remains a leading contributor to maternal morbidity and mortality, particularly in low- and middle-income countries. It is defined by hypertension and involvement of multiple organ systems, including renal, hepatic, hematologic, and neurologic pathways. The interplay of endothelial dysfunction, capillary leakage, and disrupted fluid balance in these patients increases their susceptibility to perioperative pulmonary complications. Although respiratory complications in preeclampsia are clinically significant, the true incidence of postoperative diaphragmatic dysfunction in women with severe disease is not well established. Existing literature largely emphasizes general respiratory failure, pulmonary edema, or the need for mechanical ventilation, rather than specifically evaluating diaphragmatic performance with objective methods such as ultrasound. The current study sought to determine the incidence and identify risk factors for postoperative diaphragmatic dysfunction in women with severe preeclampsia following cesarean delivery.

Primary outcomes

Eligibility information

Inclusion Criteria: * Patients with severe preeclampsia undergoing cesarean section * Gestational age \> 32 weeks Exclusion Criteria: * • Age \< 20 years. * Diabetic * Patients with neuromuscular diseases. * Patient refusal. * Contraindications to magnesium sulphate administration * Inability to obtain adequate ultrasound views

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.